Home
>
US Stocks
>
Lyell Immunopharma, Inc

Lyell Immunopharma, Inc (LYEL)

$3.5

+0.17

(+5.11%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Lyell Immunopharma, Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 3.0K → 65.0K (in $), with an average increase of 59.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.39K → -132.63M (in $), with an average decrease of 1579392.7% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 70.2%

Performance

  • $3.33
    $3.52
    $3.50
    downward going graph

    4.86%

    Downside

    Day's Volatility :5.26%

    Upside

    0.43%

    downward going graph
  • $1.77
    $8.74
    $3.50
    downward going graph

    49.43%

    Downside

    52 Weeks Volatility :79.75%

    Upside

    59.95%

    downward going graph

Returns

PeriodLyell Immunopharma, IncSector (Health Care)Index (Russel 2000)
3 Months
57.66%
0.9%
-8.3%
6 Months
-10.94%
-6.8%
-6.5%
1 Year
-30.56%
0.4%
-6.1%
3 Years
-79.28%
27.3%
21.8%

Highlights

Market Capitalization
873.6M
Book Value
$3.14
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.88
Wall Street Target Price
7.25
Profit Margin
-216.09%
Operating Margin TTM
-215.0%
Return On Assets TTM
-11.59%
Return On Equity TTM
-21.85%
Revenue TTM
84.2M
Revenue Per Share TTM
0.34
Quarterly Revenue Growth YOY
-88.2%
Gross Profit TTM
84.7M
EBITDA
-162.2M
Diluted Eps TTM
-0.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.15
EPS Estimate Next Year
-1.37
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Lyell Immunopharma, Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 107.14%

Current $3.50
Target $7.25

Company Financials

FY19Y/Y Change
Revenue
657.0K
-
Net Income
-129.4M
-
Net Profit Margin
-19.7K%
-
FY20Y/Y Change
Revenue
7.8M
↑ 1080.52%
Net Income
-204.5M
↑ 58.04%
Net Profit Margin
-2.6K%
↑ 17055.78%
FY21Y/Y Change
Revenue
10.7M
↑ 37.31%
Net Income
-250.2M
↑ 22.37%
Net Profit Margin
-2.3K%
↑ 286.84%
FY22Y/Y Change
Revenue
84.7M
↑ 695.15%
Net Income
-183.1M
↓ 26.82%
Net Profit Margin
-216.24%
↑ 2133.23%
Q4 FY21Q/Q Change
Revenue
2.8M
↑ 2.43%
Net Income
-83.7M
↑ 71.27%
Net Profit Margin
-3.0K%
↓ 1192.14%
Q1 FY22Q/Q Change
Revenue
553.0K
↓ 80.4%
Net Income
-68.1M
↓ 18.59%
Net Profit Margin
-12.3K%
↓ 9356.41%
Q2 FY22Q/Q Change
Revenue
35.7M
↑ 6363.11%
Net Income
-36.3M
↓ 46.7%
Net Profit Margin
-101.63%
↑ 12220.97%
Q3 FY22Q/Q Change
Revenue
3.0K
↓ 99.99%
Net Income
-70.3M
↑ 93.41%
Net Profit Margin
-2.3M%
↓ 2341698.37%
Q4 FY22Q/Q Change
Revenue
48.4K
↑ 1512.87%
Net Income
-8.4K
↓ 99.99%
Net Profit Margin
-17.35%
↑ 2341782.65%
Q1 FY23Q/Q Change
Revenue
65.0K
↑ 34.34%
Net Income
-132.6M
↑ 1579392.68%
Net Profit Margin
-204.0K%
↓ 204028.8%
FY19Y/Y Change
Total Assets
555.6M
-
Total Liabilities
147.6M
-
FY20Y/Y Change
Total Assets
908.3M
↑ 63.47%
Total Liabilities
189.8M
↑ 28.64%
FY21Y/Y Change
Total Assets
1.1B
↑ 24.13%
Total Liabilities
197.6M
↑ 4.1%
FY22Y/Y Change
Total Assets
937.6M
↓ 16.84%
Total Liabilities
104.3M
↓ 47.22%
Q4 FY21Q/Q Change
Total Assets
1.1B
↓ 5.92%
Total Liabilities
197.6M
↓ 6.72%
Q1 FY22Q/Q Change
Total Assets
1.1B
↓ 4.91%
Total Liabilities
190.9M
↓ 3.42%
Q2 FY22Q/Q Change
Total Assets
1.0B
↓ 4.7%
Total Liabilities
153.6M
↓ 19.5%
Q3 FY22Q/Q Change
Total Assets
977.3M
↓ 4.35%
Total Liabilities
157.2M
↑ 2.35%
Q4 FY22Q/Q Change
Total Assets
937.6M
↓ 4.06%
Total Liabilities
104.3M
↓ 33.66%
Q1 FY23Q/Q Change
Total Assets
880.5M
↓ 6.09%
Total Liabilities
96.6M
↓ 7.37%
FY19Y/Y Change
Operating Cash Flow
39.5M
-
Investing Cash Flow
-422.4M
-
Financing Cash Flow
351.2M
-
FY20Y/Y Change
Operating Cash Flow
-160.9M
↓ 507.54%
Investing Cash Flow
-273.5M
↓ 35.25%
Financing Cash Flow
476.8M
↑ 35.78%
FY21Y/Y Change
Operating Cash Flow
-126.2M
↓ 21.52%
Investing Cash Flow
-121.6M
↓ 55.55%
Financing Cash Flow
401.2M
↓ 15.84%
Q4 FY21Q/Q Change
Operating Cash Flow
-33.2M
↑ 29.93%
Investing Cash Flow
-73.9M
↓ 48.99%
Financing Cash Flow
7.4M
↓ 1493.41%
Q1 FY22Q/Q Change
Operating Cash Flow
-47.9M
↑ 44.25%
Investing Cash Flow
-26.1M
↓ 64.65%
Financing Cash Flow
2.6M
↓ 65.47%
Q2 FY22Q/Q Change
Operating Cash Flow
-44.3M
↓ 7.35%
Investing Cash Flow
25.0M
↓ 195.78%
Financing Cash Flow
2.5M
↓ 3.84%
Q3 FY22Q/Q Change
Operating Cash Flow
-37.1M
↓ 16.31%
Investing Cash Flow
-57.1M
↓ 328.17%
Financing Cash Flow
4.8M
↑ 93.73%
Q1 FY23Q/Q Change
Operating Cash Flow
-46.2M
↑ 14.76%
Investing Cash Flow
32.2M
-
Financing Cash Flow
-69.0K
↓ 108.0%

Technicals Summary

Sell

Neutral

Buy

Lyell Immunopharma, Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
50.86%
-10.94%
-30.56%
-79.28%
-79.28%
Moderna, Inc.
Moderna, Inc.
0.28%
-25.82%
-4.84%
117.92%
601.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.87%
-2.05%
17.39%
22.45%
137.1%
Seagen, Inc.
Seagen, Inc.
-1.61%
61.18%
39.62%
26.01%
217.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.63%
5.09%
23.88%
20.49%
123.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
1.78
NA
NA
-1.15
-0.22
-0.12
0.0
3.14
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lyell Immunopharma, Inc
Lyell Immunopharma, Inc
Buy
$873.6M
-79.28%
1.78
-216.09%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
601.67%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
137.1%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
217.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
123.04%
26.18
35.4%

Institutional Holdings

  • MWG Management Ltd.

    8.08%

  • Orland Properties Ltd

    6.05%

  • Vanguard Group Inc

    5.11%

  • BlackRock Inc

    4.88%

  • Foresite Capital Management IV, LLC

    4.01%

  • State Street Corporation

    3.17%

Company Information

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

Organization
Lyell Immunopharma, Inc
Employees
274
CEO
Dr. Richard D. Klausner M.D.
Industry
Services

Discover More

FAQs